Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study will be to determine whether rapid remote limb ischemic
preconditioning (RIPC) combined with acetazolamide can further reduce the incidence of acute
mountain sickness (AMS) during the 6-hour hypoxic chamber.